Moreover, Sharma et al. discovered that EGFR mutant lung cancer cell lines persisting after EGFR TKI treatment were enriched for a drug-tolerant subpopulation that may have existed prior to treatment. The gene discussed is EGFR; the disease is lung carcinoma.